Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Adverum Biotechnologies, Inc.
(Exact name of Registrant as Specified in its Charter)
Table 1 – Newly Registered Securities
| Security Type | Security Class Title |
Fee Calculation Rule |
Amount Registered(1) |
Proposed Maximum Offering Price Per Unit |
Maximum Aggregate Offering Price |
Fee Rate | Amount of Registration Fee | |||||||
| Equity | Common Stock |
Other(2) | 2,100,000(3) | $2.52(2) | $5,292,000.00 | 0.00015310 | $810.21 | |||||||
| Total Offering Amounts | – | $5,292,000.00 | – | $810.21 | ||||||||||
| Total Fees Previously Paid | – | – | – | – | ||||||||||
| Total Fee Offsets | – | – | – | – | ||||||||||
| Net Fee Due | – | – | – | $810.21 | ||||||||||
| (1) | Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Registrant’s Common Stock that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Registrant’s Common Stock. |
| (2) | Estimated in accordance with Rules 457(c) and (h) solely for the purpose of calculating the registration fee on the basis of $2.52 per share, the average of the high and low prices of the Registrant’s Common Stock on June 13, 2025 as reported on The Nasdaq Capital Market. |
| (3) | Represents shares of Common Stock that were added to the shares reserved for issuance under the Registrant’s 2024 Equity Incentive Award Plan, as amended and restated. |